November 2, 2020: Zucara Therapeutics Inc., a diabetes life sciences startup funded by TIAP and adMare BioInnovations, announced today that it has received funding from NRC IRAP and MITAS for…
– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials – – Series A Financing led by the Perceptive Xontogeny Venture Fund – TORONTO, March 31, 2020 (GLOBE…
Toronto & Vancouver, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent…
Toronto and Vancouver, Canada: Zucara Therapeutics Inc., a diabetes life sciences company advancing the first once-daily therapeutic to prevent low blood glucose levels (hypoglycemia), has secured US$3.9 million in non-dilutive funding…
VANCOUVER and TORONTO, Canada — January 8, 2018 - Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes,…
New paper published in The Lancet Diabetes & Endocrinology recommends exercise guidelines for type 1 diabetes patients and healthcare providers. Experts from JDRF, the leading global organization focused on type…
VANCOUVER and TORONTO, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced…
This new license is an important step forward in bringing a new drug therapy closer to patients living with diabetes as it will enable us to access a promising lead…
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca